5 days ago
DFTX
AnalystsSumant KulkarniSumant Kulkarni's Stock Forecasts
AnalystsSumant Kulkarni
Analyst Ranking
Top 19%
#1057 out of 5515 analysts
Average Return
+4.79%
Win Rate
45%63 out of 139
Risk vs Reward
Poor
Good
Sumant Kulkarni's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cervomed IncCRVO | +344.62% | $1.95 | $8.67 | 2024-12-11 - 2025-12-10 | Strong Buy |
Definium Therapeutics IncDFTX | +231.71% | $11.70 | $38.81 | 2025-11-07 - 2026-09-18 | Strong Buy |
Compass Pathways PLCCMPS | +169.33% | $5.64 | $15.19 | 2026-03-26 - 2026-09-18 | Strong Buy |
Compass Pathways PLCCMPS | +161.52% | $4.34 | $11.35 | 2025-08-01 - 2026-07-31 | Strong Buy |
Sage Therapeutics IncSAGE | +157.05% | $30.01 | $77.14 | 2020-04-08 - 2021-04-08 | Strong Buy |
Sumant Kulkarni Analyst Color
Get additional color on Sumant Kulkarni's coverage of popular stocks
a month ago
DFTX
2 months ago
NBIX
2 months ago
MPLT
2 months ago
ATAI
3 months ago
ACAD
3 months ago
CMPS
2 years ago
CRVO
3 years ago
HELP
3 years ago
SAGE
3 years ago
HELP
Sumant Kulkarni's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Definium Therapeutics IncDFTX | 7 | Strong Buy | $78.00 | +100.98% | Maintains | 5 days ago |
Annovis Bio IncANVS | 6 | Strong Buy | $17.00 | +1,391.23% | Maintains | a month ago |
Cervomed IncCRVO | 7 | Strong Buy | $18.00 | +640.74% | Maintains | a month ago |
Stoke Therapeutics IncSTOK | 7 | Strong Buy | $58.00 | +104.01% | Maintains | 2 months ago |
Neurocrine Biosciences IncNBIX | 13 | Strong Buy | $210.00 | +43.61% | Maintains | 2 months ago |
Biogen IncBIIB | 15 | Strong Buy | $248.00 | +15.08% | Maintains | 2 months ago |
Maplight Therapeutics IncMPLT | 3 | Strong Buy | $24.00 | +119.78% | Maintains | 2 months ago |
Zevra Therapeutics IncZVRA | 11 | Strong Buy | $20.00 | +72.27% | Maintains | 2 months ago |
Ataibeckley IncATAI | 7 | Hold | $8.00 | +8.84% | Downgrades | 2 months ago |
Cybin IncHELP | 10 | Strong Buy | $42.00 | +239.53% | Maintains | 3 months ago |
Acadia Pharmaceuticals IncACAD | 12 | Strong Buy | $36.00 | +31.92% | Maintains | 3 months ago |
Compass Pathways PLCCMPS | 7 | Strong Buy | $20.00 | +31.67% | Maintains | 3 months ago |
Clene IncCLNN | 7 | Strong Buy | $48.00 | +1,003.45% | Maintains | 6 months ago |
Gh Research PLCGHRS | 5 | Strong Buy | $39.00 | +38.00% | Maintains | 8 months ago |
Sage Therapeutics IncSAGE | 7 | Hold | $8.50 | N/A | Maintains | a year ago |
Voyager Therapeutics IncVYGR | 4 | Strong Buy | $12.00 | N/A | Maintains | 2 years ago |
Intra Cellular Therapies IncITCI | 5 | Hold | $132.00 | N/A | Downgrades | 2 years ago |
Bioxcel Therapeutics IncBTAIQ | 7 | Strong Buy | $80.00 | N/A | Maintains | 2 years ago |
Tvardi Therapeutics IncTVRD | 4 | Hold | $12.00 | N/A | Downgrades | 2 years ago |
Zynerba Pharmaceuticals IncZYNE | 2 | Hold | $1.11 | N/A | Downgrades | 3 years ago |
Quince Therapeutics IncQNCX | 2 | Hold | N/A | N/A | Downgrades | 5 years ago |
Biohaven Pharmaceutical Holding Co LtdBHVN1 | 3 | Strong Buy | $150.00 | N/A | Maintains | 5 years ago |
Alder Biopharmaceuticals IncALDR | 2 | Strong Buy | $20.00 | N/A | Maintains | 8 years ago |
Avexis IncAVXS | 1 | Hold | $120.00 | N/A | Maintains | 9 years ago |
Teva Pharmaceutical Industries LtdTEVA | 1 | Strong Buy | N/A | N/A | Upgrades | 10 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.